Akari Historical Financial Ratios
| AKTX Stock | USD 1.14 0.11 10.68% |
Akari Therapeutics is presently reporting on over 101 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Dividend Yield of 0.0, Days Sales Outstanding of 0.0 or Invested Capital of 6.4 M will help investors to properly organize and evaluate Akari Therapeutics PLC financial condition quickly.
Akari |
About Akari Financial Ratios Analysis
Akari Therapeutics PLCFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Akari Therapeutics investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Akari financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Akari Therapeutics history.
Akari Therapeutics Financial Ratios Chart
Add Fundamental
Invested Capital
Invested capital represents the total cash investment that shareholders and debt holders have contributed to Akari Therapeutics PLC. There are two different methods for calculating Akari Therapeutics PLC invested capital: operating approach and financing approach. Understanding Akari Therapeutics invested capital allows investors to calculate measures of performance such as return on invested capital or return on capital employed.Average Payables
The average amount owed to suppliers and creditors over a specific period, reflecting the company's payment cycle and credit terms with suppliers.Payables Turnover
A liquidity ratio that shows how quickly a company pays off its suppliers by dividing total purchases by average accounts payable.Most ratios from Akari Therapeutics' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Akari Therapeutics PLC current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Akari Therapeutics PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. At this time, Akari Therapeutics' Average Payables is fairly stable compared to the past year. ROIC is likely to rise to 77.06 in 2024, despite the fact that PTB Ratio is likely to grow to (63.35).
| 2021 | 2022 | 2024 (projected) | Net Debt To EBITDA | 0.54 | 0.57 | 0.22 | Intangibles To Total Assets | 0.001968 | 0.00122 | 0.003375 |
Akari Therapeutics fundamentals Correlations
Click cells to compare fundamentals
Akari Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Akari Therapeutics fundamentals Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Ptb Ratio | 8.35 | 4.72 | 11.59 | 16.39 | (66.68) | (63.35) | |
| Book Value Per Share | 4.19 | 7.83 | 2.59 | 0.57 | (0.0468) | (0.0444) | |
| Free Cash Flow Yield | (0.0454) | (0.38) | (0.29) | (0.73) | (1.08) | (1.02) | |
| Operating Cash Flow Per Share | (13.39) | (10.73) | (8.78) | (6.89) | (3.36) | (3.53) | |
| Pb Ratio | 8.35 | 4.72 | 11.59 | 16.39 | (66.68) | (63.35) | |
| Free Cash Flow Per Share | (13.39) | (10.73) | (8.78) | (6.89) | (3.36) | (3.53) | |
| Roic | (5.7) | (1.25) | (3.13) | (5.06) | 73.39 | 77.06 | |
| Net Income Per Share | (23.77) | (11.14) | (8.2) | (2.23) | (2.04) | (2.15) | |
| Payables Turnover | 0.0156 | 0.002635 | 0.002307 | 0.003916 | 0.002394 | 0.002274 | |
| Cash Per Share | 6.26 | 8.9 | 4.36 | 4.24 | 0.79 | 0.75 | |
| Pocfratio | (2.61) | (3.45) | (3.42) | (1.36) | (0.93) | (0.98) | |
| Pfcf Ratio | (2.61) | (3.45) | (3.42) | (1.36) | (0.93) | (0.98) | |
| Days Payables Outstanding | 23.4K | 138.5K | 158.2K | 93.2K | 152.5K | 160.1K | |
| Roe | (5.67) | (1.42) | (3.17) | (3.89) | 43.7 | 45.89 | |
| Ev To Operating Cash Flow | (2.15) | (2.62) | (2.92) | (0.75) | (0.7) | (0.73) | |
| Pe Ratio | (1.47) | (3.32) | (3.66) | (4.21) | (1.53) | (1.6) | |
| Return On Tangible Assets | (2.12) | (1.0) | (1.51) | (0.5) | (2.31) | (2.42) | |
| Ev To Free Cash Flow | (2.15) | (2.62) | (2.92) | (0.75) | (0.7) | (0.73) | |
| Earnings Yield | (0.68) | (0.3) | (0.27) | (0.24) | (0.66) | (0.62) | |
| Intangibles To Total Assets | 0.002911 | 0.001535 | 0.001968 | 0.00122 | 0.003215 | 0.003375 | |
| Net Debt To E B I T D A | 0.36 | 0.23 | 0.69 | 0.54 | 0.57 | 0.22 | |
| Current Ratio | 1.88 | 3.37 | 1.91 | 1.15 | 0.95 | 0.9 | |
| Tangible Book Value Per Share | 4.16 | 7.82 | 2.58 | 0.57 | (0.0496) | (0.0472) | |
| Graham Number | 47.34 | 44.32 | 21.86 | 5.37 | 1.47 | 1.39 | |
| Shareholders Equity Per Share | 4.19 | 7.83 | 2.59 | 0.57 | (0.0468) | (0.0444) | |
| Graham Net Net | (1.37) | 5.43 | 1.52 | (0.0108) | (0.15) | (0.14) | |
| Enterprise Value Over E B I T D A | (1.06) | (2.17) | (3.2) | (0.7) | (0.68) | (0.71) | |
| Price Earnings Ratio | (1.47) | (3.32) | (3.66) | (4.21) | (1.53) | (1.6) | |
| Price Book Value Ratio | 8.35 | 4.72 | 11.59 | 16.39 | (66.68) | (63.35) | |
| Price Earnings To Growth Ratio | (8.24E-4) | 0.0625 | 0.14 | 0.0578 | 0.18 | 0.17 | |
| Days Of Payables Outstanding | 23.4K | 138.5K | 158.2K | 93.2K | 152.5K | 160.1K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Akari Stock Analysis
When running Akari Therapeutics' price analysis, check to measure Akari Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Akari Therapeutics is operating at the current time. Most of Akari Therapeutics' value examination focuses on studying past and present price action to predict the probability of Akari Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Akari Therapeutics' price. Additionally, you may evaluate how the addition of Akari Therapeutics to your portfolios can decrease your overall portfolio volatility.